Pharmacoeconomic Assessment of 13-Valent Pneumococcal Conjugate Vaccine in Immunization of Children in Russian Federation

Рудакова, А. В.; Баранов, А.А.; Lobzin, Yu. V.; Намазова-баранова, Л. С.; Брико, Н И; Таточенко, В. К.; Харит, С. М.; Сидоренко, С В; Koroleva, Irina; Козлов, Р С; Mayanskii, N.A.; Костинов, М. П.; Снегова, Н Ф

doi:10.15690/vsp.v13i1.911

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S. pneumoniae serotypes/serogroups have been investigated in Russia ; three PCVs, PCV7, PCV10 and PCV13, have been registered for children. The molecular characteristics of S. pneumoniae have not yet been reported in Siberian Russia (Krasnoyarsk), which is located between the European and Far Eastern regions.…”

mentioning

confidence: 99%

Molecular characterization of Streptococcus pneumoniae, particularly serotype19A/ST320, which emerged in Krasnoyarsk, Russia

Протасова¹,

Wan²,

Бахарева

et al. 2017

Microbiology and Immunology

View full text Add to dashboard Cite

Streptococcus pneumoniae, a common human pathogen, colonizes the nasopharynx and causes diseases including acute otitis media (AOM). Herein, pneumococcal serotype distributions in children before and after PCV7 vaccination and in patients with pneumococcal disease in Siberian Russia (Krasnoyarsk) are reported. Analyses included antimicrobial susceptibility testing, sequence typing (ST), pulsed field gel electrophoresis, virulence‐related surface protein gene (VSG) typing with novel primers and structural analysis by scanning electron microscopy. In healthy children (HC) prior to administration of PCV7, drug‐susceptible serotype23F/ST1500 was a major pneumococcal genotype. In the PCV7 trial, multidrug‐resistant serotype19A/ST320 emerged in vaccinees after PCV7, exhibiting a PCV7‐induced serotype replacement. Multidrug‐resistant serotype19A/ST320 was evident in patients with AOM. Community‐acquired pneumonia (CAP) isolates showed genetic similarities to the AOM (ST320) genotype, constituting a common non‐invasive AOM–CAP group. In contrast, meningitis isolates were more divergent. Overall, 25 ST types were identified; five (20%) of which were Krasnoyarsk‐native. Regarding VSGs, PI‐1 (rlrA/rrgB), PI‐2 (pitA/B), psrP and cbpA were present at 54.3%, 38.6%, 48.6%, and 95.7%, respectively, with two major VSG content types, PI‐1−/PI‐2−/psrP +/cbpA + and PI‐1+/PI‐2+/psrP ‐/cbpA +, being found for HC and non‐invasive diseases, respectively. A major clone of serotype19A/ST320 (PI‐1+/PI‐2+) produced the longest pneumococcal wire (pilus) structures in colonies. ST1016 (PI‐1−/PI‐2−) in HC had HEp‐2 cell‐adherent pili. These results suggest that serotype19A/ST320 and related genotypes, with the VSG content type PI‐1+/PI‐2+/psrP −/cbpA +, emerged in vaccinees after PCV7 in Siberia, accompanying diseases in non‐vaccinated children, and that some genotypes (serotypes19A/ST320 and 18/ST1016) produced novel pneumococcal structures, predicting their roles in colony formation and adherence.

show abstract

mentioning

confidence: 99%

Molecular characterization of Streptococcus pneumoniae, particularly serotype19A/ST320, which emerged in Krasnoyarsk, Russia

Протасова¹,

Wan²,

Бахарева

et al. 2017

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Вакцинация взрослых и детей с СД должна проводиться по такому же календарю, что вакцинация населения в целом. При работе с пациентами необходимо отражать положительные моменты и факты преимущества вакцинации, которые способствовали бы активной реализации программ вакцинации данной когорты пациентов [47,48,49].…”

Section: заключениеunclassified

Approaches to vaccine prophilaxis of respiratory infections in patients with diabetes mellitus in the modern epidemiological situation

Тарасова¹,

Kostinov²,

Paramonova³

2020

Diabetes mellitus

View full text Add to dashboard Cite

This review highlights the problems of vaccine prophylaxis of pneumococcal infection and influenza in patients with type 1 and type 2 diabetes mellitus (CD1 and CD2). The features of pneumococcal infection and influenza in conditions of unsatisfactory compensation of the disease are described. The necessity of protection against pneumococcal infection and influenza in the modern epidemiological situation is justified. Results of efficacy and safety of vaccination, including those in children with type 1 diabetes mellitus, are established. The existing foreign and domestic regulatory documents on vaccine prevention of actual infections are shown.Despite the available documents on vaccination of patients with diabetes, there are problems with inadequate immunization coverage of patients with CD1 and CD2 due to the lack of precise clinical recommendations for the management of these categories both inpatient and outpatient as these recommendations do not cover the questions of vaccine prophylaxis. In Russian studies only the treatment regimens are evaluated without taking into account the fact that vaccines are related to medicines and that the prevention of respiratory infections is a curative measure and can inhibit the development of complications of diabetes.It is necessary to coordinate the work of general practitioners, pediatricians, therapists and the efforts of endocrinologists to increase the coverage of immunization of patients with various forms of diabetes mellitus.

show abstract

Modern Approaches to Vaccinal Prevention of a Pneumococcal Infection in Adults Patients with Diabetes Mellitus (Literature Review)

Парамонова¹,

Postnikova²,

Костинов³

et al. 2018

Epidemiology and Vaccine Prevention

View full text Add to dashboard Cite

At present, pneumococcal infections remain a major cause of morbidity and mortality around the world, being one of the ten leading causes of death worldwide. Some medical conditions, like diabetes mellitus (DM) are associated with an increased risk of pneumococcal infections and vaccination was calculated to be highly cost-effective among those adults with an increased risk. The article analyzes world data on pneumococcal infection morbidity rate among diabetes mellitus patients and possible ways of reducing it through immunization. In December 2011, the Food and Drug Administration (FDA) licensed 13-valent pneumococcal conjugate vaccine (PCV13) for prevention of pneumonia and invasive pneumococcal disease in adults aged ≥ 50 years. However, the efficacy of PCV in individuals with specific comorbidities is yet unknown. The article presents the findings of research which investigated the efficacy of antipneumococcal vaccination among diabetes mellitus patients. It also gives data of first-hand experience of 13-valent pneumococcal conjugate vaccine use (Prevenar 13, Pfizer).

show abstract

Pharmacoeconomic Assessment of 13-Valent Pneumococcal Conjugate Vaccine in Immunization of Children in Russian Federation

Cited by 5 publications

References 10 publications

Molecular characterization of Streptococcus pneumoniae, particularly serotype19A/ST320, which emerged in Krasnoyarsk, Russia

Molecular characterization of Streptococcus pneumoniae, particularly serotype19A/ST320, which emerged in Krasnoyarsk, Russia

Approaches to vaccine prophilaxis of respiratory infections in patients with diabetes mellitus in the modern epidemiological situation

Modern Approaches to Vaccinal Prevention of a Pneumococcal Infection in Adults Patients with Diabetes Mellitus (Literature Review)

Contact Info

Product

Resources

About